Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

ANSS total score.

In the 53-week non-inferiority trial, patients were randomly assigned to receive flexible dose paliperidone palmitate plus orally supplemented placebo (PP+Pbo) or flexible dose risperidone LAT plus orally supplemented risperidone (LAT RIS+RIS). All injections were administered in the gluteal muscle. Patients in the PP+Pbo group received two 50 mg eq. injections one week apart, followed by injections of 25, 50, 75 or 100 mg eq. every 4 weeks. Patients in the LAT RIS+RIS group received a placebo injection on day 1, 25 mg risperidone LAT on days 8 and 22 and injections every 2 weeks of 25, 37.5 or 50 mg. The primary endpoint was the change in PANSS total score from baseline to endpoint. Non-inferiority was planned to be demonstrated if paliperidone palmitate was no worse than risperidone LAT, as measured by a 95% confidence interval of more than -5 points in the change in PANSS total score.

Although patients receiving both paliperidone palmitate and risperidone LAT had similar improvements in PANSS scores at the end of the 53 week trial, the difference between paliperidone palmitate and risperidone LAT in the least square adjusted mean change in PANSS score was -2.6 points, with a 95% confidence interval (CI) of (-5.84, 0.61). As the lower limit (-5.84) of the CI was less than -5, non-inferiority of paliperidone palmitate versus risperidone LAT was not demonstrated using this dosing regimen. Comparative plasma concentrations of paliperidone in the PP+Pbo group were consistently lower than concentrations of active moiety in the LAT RIS+RIS group until day 260. Although non-inferiority was not demonstrated using this dosing regimen, it is not possible to conclude superiority of LAT RIS+RIS over PP+Pbo using the results from this study. Overall rates of adverse events were similar in both groups: 76% for paliperidone palmitate and 79% for risperidone LAT. The most common (>10% in either group) TE
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... (PRWEB) June 03, 2015 GEA's ... , which is a standalone, fully-equipped laboratory unit that ... for limited productions in pilot plants. The Pantherâ„¢ NS3006L ... its compact design allows for easy installation with simple ... products. This homogenizer can be used in many different ...
(Date:6/2/2015)... June 2, 2015 /CNW/ - Shell today celebrated the North ... premium category with an exhibit the size of a ... interactive demonstrations for media and the public, and special ... NiTRO+ Premium Gasoline provides the best total engine protection ... engine wear, gunk and corrosion. "With the ...
(Date:6/2/2015)... YORK , Jun. 02, 2015 Tauriga ... a diversified life sciences company with interests in ... proprietary synthetic biology platform technology, today announced that ... Typenex Co-Investment, LLC ("Typenex") in exchange for a ... 16, 2015, the Company and Typenex entered into ...
(Date:6/2/2015)... , June 02, 2015 Research and ... "Genotyping Market by Technology, Application & by Products ... offering. The global genotyping market is expected ... in 2015, at a CAGR of 22.3% during the ... growth will be attributed to the availability of a ...
Breaking Biology Technology:GEA Announces the Pantherâ„¢ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2
... the Project on Emerging Nanotechnologies (PEN) at the ... variety of voluntary options available for the oversight ... Voluntary Initiatives, Regulation, and Nanotechnology Oversight: Charting a ... Center for Environmental Policy at American University, provides ...
... today released the first in a series of video ... technology correspondent Miles O,Brien and currently airing nationally on ... quick look at what happens when genius meets possibility: ... shaping our world. The 26-part video series is ...
... ... if ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s ... (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Biology Technology:OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9OncoGenex Reports Third Quarter Financial Results 10OncoGenex Reports Third Quarter Financial Results 11OncoGenex Reports Third Quarter Financial Results 12OncoGenex Reports Third Quarter Financial Results 13
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... drug delivery methods that are more effective and less ... Chemists at The University of Nottingham are developing new ... do not damage the latest generation of delicate biopharmaceutical ... medical treatment. Conventional methods of coating drugs can ...
... Conservation International (CI) today announced a partnership with ... more than 4,000 acres of the Philippines Peablanca ... Northeastern part of one of the nations main ... local communities will receive additional benefits from agroforestry ...
... unresolved as to whether the Neanderthals died out ... of deteriorating climatic conditions. Although scientists have gained ... difficult to pinpoint the climatic character at the ... by an international team of researchers, published this ...
Cached Biology News:Using green chemistry to deliver cutting-edge drugs 2Using green chemistry to deliver cutting-edge drugs 3Using green chemistry to deliver cutting-edge drugs 4Conservation International and Toyota partner to protect Philippines' rain forests 2Conservation International and Toyota partner to protect Philippines' rain forests 3Climate -- no smoking gun for Neanderthals 2
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Kit is manufactured for DNA purification from ... to UV light. The Purification of DNA ... for DNA-cloning work. The conventional method of ... of UV light damages DNA and significantly ...
... antibody raised against a partial recombinant MAK. ... ~ 457 a.a) partial recombinant protein with GST ... Accession: BC039825 ... OMIM: 154235, GeneID: ...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: